Clinical Trial Update: Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chemoradiation plus durvalumab, followed by surgery and adjuvant durvalumab, in surgically resectable Stage III (N2) non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Greg Durm, MD | Conditions: Non Small Cell Lung Cancer, Stage III Non-small-cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-11-01